ClinicalTrials.gg
CompletedNCT00771004Updated Jul 5, 2010

Efficacy of Pioglitazone on Myocardial Function in Patients Undergoing Coronary Stent Implantation.

A Phase 2 interventional study of Pioglitazone and Placebo in Oxidative Stress, Coronary Artery Disease and Type 2 Diabetes, sponsored by Takeda. Completed at 7 sites in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-07-05.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 365 studies in Coronary Artery Disease with a site in Germany — 46 open to participants now, 71 under way, 3 of them phase 3. Coronary Artery Disease · Germany.

Enrollment
197th of 248
63 · median 265
Started
2006
with 14 others
Phase 2
19 of 365
1 open now
Registered
79th of 365
by date

Among the 365 studies in Coronary Artery Disease with a site in Germany, this one is the 197th largest by enrollment of the 248 interventional ones that give a count, is one of 15 that started in 2006, is one of 19 in phase 2, and was the 79th registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

46 of the 365 studies in Coronary Artery Disease with a site in Germany are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 365 studies in Coronary Artery Disease with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this study is to determine the effects of pioglitazone, once daily (QD), on heart functioning before, during and after stent implantation.

Read the detailed description

Type 2 diabetes increases the risk of coronary heart disease at least by two to three fold compared with non-diabetic subjects. Moreover, prospective studies have shown a significant correlation between several glycemic confounders and morbidity from coronary heart disease even in patients without diabetes mellitus. In patients with previously diagnosed coronary heart disease, impaired glucose tolerance was found in 30 to 67 %. The cardiovascular risk of patients with insulin resistance, with or without glucose intolerance has become more and more apparent within recent years and quantitative coronary angiographic studies have revealed a correlation between the severity of coronary heart disease and impaired glucose tolerance.

A new pharmaceutical class for the intervention of insulin resistance, the peroxisome proliferator activated receptor (gamma) agonists have been successfully introduced in the treatment of type 2 diabetes. Beyond their metabolic effects on glucose and lipid metabolism, peroxisome proliferator activated receptor (gamma) agonists show to exert a couple of pleiotropic, anti-inflammatory and vasoprotective effects in patients with type 2 diabetes and impaired glucose tolerance.

The incidence and severity of peri-procedural myocardial injury during percutaneous coronary interventions with stent implantation in diabetic and in non-diabetic patients is an important prognostic confounder for the patient. Different laboratory biomarkers have been investigated as diagnostic tools for the estimation of the risk of peri-procedural myocardial injury. Recent studies have convincingly demonstrated that the risk of subsequent ischemic heart events is related to the extent of cardiac troponin or CK-MB increase after coronary intervention, and the prognosis for these individuals is usually worse than that for patients who do not develop an increase in these biomarkers.

In a recent trial it was shown that pretreatment with atorvastatin could reduce procedural myocardial injury in elective coronary intervention. The incidence of Troponin I increase was 48% in the placebo group compared to 20% in the atorvastatin group.

The aim of this study is to investigate the effect of pioglitazone on the incidence of peri-procedural myocardial injury in patients undergoing percutaneous coronary interventions with stent implantation. Total participation time is anticipated to be 3 weeks.

03

Conditions studied

  • Oxidative Stress
  • Coronary Artery Disease
  • Type 2 Diabetes

Keywords

  • drug effects
  • Type II Diabetes
  • Angioplasty, Transluminal, Percutaneous Coronary
  • Drug Therapy
  • Heart
  • physiology
  • function
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stable coronary artery disease with planned percutaneous coronary intervention with stent implantation.
  • Type II-diabetics and/or an IRIS II score greater than or equal to 50 (measure for the identification of patients with insulin resistance and increased vascular risk).
  • Females of who are sexually active must agree to use adequate , and can neither be pregnant nor lactating from Screening throughout the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • A planned percutaneous coronary intervention with stent implantation less than 15 days after the screening visit.
  • Planned multi-vessel intervention.
  • Use of systemic within the last 3 months prior to screening visit.
  • Anamnestic history of to the study drugs or to drugs with similar chemical structures.
  • History of severe or multiple allergies.
  • Treatment with any other drug within 3 months before trial entry or earlier participation in the present study.
  • Have had more than one unexplained episode of severe hypoglycemia (defined as requiring assistance of another person due to disabling hypoglycemia) within 6 months prior to screening visit.
  • Progressive fatal disease.
  • History of drug or alcohol abuse within the last 10 years.
  • A history of significant cardiovascular (New York Health Association stage II - IV), respiratory, gastrointestinal, hepatic ( greater than 2.5 times the normal reference range), renal (creatinine greater than 1.2 mg/dL in women and greater than 1.5 in men and/or less than 45), neurological, psychiatric and/or hematological disease as judged by the Investigator.
  • Pre-treatment with peroxisome proliferator-activated receptor (gamma) agonists within the 3 months prior to screening.
  • If insulin therapy applicable: initiation of insulin therapy within the last 3 months.
  • If statin therapy applicable: change of medication within the last 4 weeks.
  • Myocardial infarction within 3 months prior to screening visit.
  • Blood donation within last 30 days.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Pioglitazone 30 mg to 45 mg QD

    Drug: Pioglitazone

  • Placebo comparator
    Placebo QD

    Drug: Placebo

Interventions

  • Pioglitazone 30 mg, tablets, orally, once daily for one week; increased to Pioglitazone 45 mg, tablets, orally, once daily for up to two weeks.

    Also known as: ACTOS®, AD4833

  • DrugPlacebo

    Pioglitazone placebo-matching tablets, orally, once daily for up to three weeks.

06

What researchers measure

Primary outcomes

  1. Incidence of Cardiac Troponin I elevation (greater than 1 upper limit of normal) post-percutaneous coronary intervention with stent implantation.

    Time frame: 24 hours post stent implantation.

Secondary outcomes

  1. Incidence of Creatine Kinase (Myocard-type) post-percutaneous coronary intervention with stent implantation.

    Time frame: 24 hours post stent implantation.

  2. Mean peak values of Troponin I and Creatine Kinase (Myocard-type) post-percutaneous coronary intervention with stent implantation.

    Time frame: Hours: 2, 6 and 12 and 24 post stent implantation.

  3. Frequency of Doppler-detected microembolism measured by high intensity transient signals during percutaneous coronary intervention with stent implantation (sub-study Jena only).

    Time frame: Duration of stent implantation surgery.

  4. Time course of Troponin I Laboratory Procedure.

    Time frame: Visits: 2, 3, 4, 5, 6, 7, and 8 or Final Visit.

  5. Time course of high-sensitive-C-Reactive Peptide Laboratory Procedure.

    Time frame: Visits: 2, 3, 4, 5, 6, 7, and 8 or Final Visit.

  6. Time course of nitrotyrosine Laboratory Procedure.

    Time frame: Visits: 2, 3, 4, 5, 6, 7, and 8 or Final Visit.

  7. Time course of Asymmetric dimethylarginine Laboratory Procedure.

    Time frame: Visits: 2, 3, 4, 5, 6, 7, and 8 or Final Visit.

  8. Time course of E-selectin Laboratory Procedure.

    Time frame: Visits: 2, 3, 4, 5, 6, 7, and 8 or Final Visit.

  9. Time course of Myoglobin Laboratory Procedure.

    Time frame: Visits: 2, 3, 4, 5, 6, 7, and 8 or Final Visit.

  10. Time course of Visfatin Laboratory Procedure.

    Time frame: Visits: 2, 3, 4, 5, 6, 7, and 8 or Final Visit.

  11. Time course of Proinsulin intact Laboratory Procedure.

    Time frame: Visits: 1 and 7 or Final Visit.

  12. Time course of Adiponectin Laboratory Procedure.

    Time frame: Visits: 1 and 7 or Final Visit.

07

Study locations

7 sites
  • Frankfurt, Hessen, Germany
  • Kassel, Hessen, Germany
  • Wiesbaden, Hessen, Germany
  • Wuppertal, Nordrhein-Westfalen, Germany
  • Mainz, Rheinland-Pfalz, Germany
  • Jena, Thüringen, Germany
  • Hamburg, Germany
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2008
First posted
Oct 10, 2008
Start
Aug 2006
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Last update
Jul 5, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00771004
Lead sponsor
Takeda
First posted
Oct 10, 2008
Start date
Aug 2006
Primary completion
Feb 2009
Completion
Feb 2009
Last update
Jul 5, 2010

Study contacts

Medical Adviser Clinical Research
study director · Takeda Pharma Gmbh, Aachen (Germany)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pioglitazone

Start the discussion